Zealand Pharma

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zealand Pharma announces update to 2020 financial guidance

Total number of shares and voting rights in Zealand Pharma at December 31, 2020

Zealand Pharma announces data from the first phase 3-trial with dasiglucagon in Congenital Hyperinsulinism (CHI)

Financial calendar for Zealand Pharma in 2021

Total number of shares and voting rights in Zealand Pharma at November 30, 2020

In this article we will take a look at whether hedge funds think Zealand Pharma A/S (NASDAQ:ZEAL) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks historically outperformed the market after adjusting for known risk factors.

Where Do Hedge Funds Stand On Zealand Pharma A/S (ZEAL)?

Zealand Pharma A/S (ZLDPF) CEO Emmanuel Dulac on Q3 2020 Results - Earnings Call Transcript

Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q3 2020 Results - Earnings Call Transcript

Zealand Pharma continues to advance clinical programs and commercial launch capabilities and presents financial results for the first nine months of 2020

Zealand Pharma:

Zealand Pharma hosts conference call on November 12 at 4 pm CET (10am ET) to present third quarter results for 2020

Total number of shares and voting rights in Zealand Pharma at September 30, 2020

Correction: Zealand Pharma announces amendments to its Articles of Association following the granting of warrants

Zealand Pharma announces amendments to its Articles of Association following the granting of warrants

Zealand Pharma grants warrants and restricted share units under the employee warrant program and management long-term incentive program

Zealand Pharma builds Global Medical Affairs function with world-renowned experts

Total number of shares and voting rights in Zealand Pharma at August 31, 2020

Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q2 2020 Results - Earnings Call Transcript

Zealand Pharma announces acceleration of U.S. commercial operations through the completion of the Valeritas acquisition; FDA acceptance of New Drug Application submission for the dasiglucagon HypoPal® rescue pen; pipeline progress including

Zealand Pharma hosts conference call on August 13 at 4 pm CET (10am ET) to present second quarter results for 2020

Zealand Pharma Continues to Build Investor Relations and Communications Function with the Appointment of Mads Kronborg

Zealand Pharma Expands U.S. Operations, Opens New Boston Office

Zealand (ZEAL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zealand (ZEAL) Surges: Stock Moves 9.1% Higher

Total number of shares and voting rights in Zealand Pharma at June 30, 2020

Zealand's (ZEAL) partner, Boehringer Ingelheim, is developing BI 456906, a long-acting GLP-1/glucagon dual agonist, as a treatment for obesity and type 2 diabetes.

Zealand Announces Dosing Initiation in Type 2 Diabetes Study

News for Zealand Pharma Stock (ZEAL)